This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
20 Jan 2011

Sanofi-Aventis May Prolong Offer For US Genzyme

Sanofi-Aventis’ offer for biotech firm Genzyme ends this Friday. The deadline is likely to be extended once again and the offer may see an increase towards USD80 per share.

This Friday is the deadline of Sanofi-Aventis’s USD69 (EUR51.19) per share offer for US biotech firm Genzyme. However, according to sources in the know, the deadline is expected to be changed once again, Reuters said.

 

In spite of the revision of the deadline, the two companies have advanced their negotiations for this offer in direct talks and the steps they are making forward are considerable, as news agency reported.

 

The offer evaluating Genzyme at USD18.5bn ends this Friday. Sanofi-Aventis already extended its proposal in December when it had secured a mere 1% of the US company stock.

 

An extension is seen as a formality to enable the possible

Related News